Evidence map›Paper›PMID 31338922›Full record

ArticleMolecular oncology2019

CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation.

Edward Abadir, Robin E Gasiorowski, Kaitao Lai, Fiona Kupresanin, Adelina Romano, Pablo A Silveira, Tsun-Ho Lo, Phillip D Fromm, Marina L Kennerson, Harry J Iland and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Edward AbadirDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.
Robin E GasiorowskiDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.
Kaitao LaiSydney Medical School, University of Sydney, Australia.
Fiona KupresaninDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.
Adelina RomanoDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.
Pablo A SilveiraDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.
Tsun-Ho LoDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.
Phillip D FrommDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.
Marina L KennersonSydney Medical School, University of Sydney, Australia.
Harry J IlandSydney Medical School, University of Sydney, Australia.
P Joy HoSydney Medical School, University of Sydney, Australia.
P Mark HogarthImmune Therapies, Burnet Institute, Melbourne, Australia.
Kenneth BradstockDepartment of Haematology, Westmead Hospital, Sydney, Australia.
Derek N J HartDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.
Georgina J ClarkDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.ORCID 0000-0001-7894-232X
The University of Sydney · AUAnzac Research Institute · AUBurnet Institute · AUWestmead Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-based therapy in acute myeloid leukemia (AML) has been marred by significant hematologic toxicity due to targeting of both hematopoietic stem and progenitor cells (HSPCs). Achieving greater success with therapeutic antibodies requires careful characterization of the potential target molecules on AML. One potential target is CD300f, which is an immunoregulatory molecule expressed predominantly on myeloid lineage cells. To confirm the value of CD300f as a leukemic target, we showed that CD300f antibodies bind to AML from 85% of patient samples. While one CD300f monoclonal antibody (mAb) reportedly did not bind healthy hematopoietic stem cells, transcriptomic analysis found that CD300f transcripts are expressed by healthy HSPC. Several CD300f protein isoforms exist as a result of alternative splicing. Importantly for antibody targeting, the extracellular region of CD300f can be present with or without the exon 4-encoded sequence. This results in CD300f isoforms that are differentially bound by CD300f-specific antibodies. Furthermore, binding of one mAb, DCR-2, to CD300f exposes a structural epitope recognized by a second CD300f mAb, UP-D2. Detailed analysis of publicly available transcriptomic data indicated that CD34

Indexed as

Antibodies, MonoclonalAntineoplastic Agents, ImmunologicalCell Line, TumorEpitopesHumansLeukemia, Myeloid, AcuteMolecular Targeted TherapyMonocytesReceptors, ImmunologicAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalCD300LF protein, humanEpitopesReceptors, Immunologicacute myeloid leukemiaantibody epitopesCD300fcell surface targetingisoform expressionmonoclonal antibodies

Identifiers

PMID31338922
PMCPMC6763785
OpenAlexW2962864268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.